Overview Financials News + Filings Key Docs Ownership
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Pharvaris N.V.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/07/2023 |
6-K
| Quarterly results|
Docs:
|
"6-K",
"Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update • Enrollment completed in Phase 2 CHAPTER-1 prophylactic study; top-line data anticipated by YE2023 • Clinical hold lifted on deucrictibant for the on-demand treatment of HAE; initiation of global Phase 3 clinical study anticipated by YE2023 • Completed $70 million private placement; cash and cash equivalents of €179 million as of June 30, 2023 Zug, Switzerland, August 7, 2023 – Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today reported financial results for the second quarter ended June 30, 2023 and provided a business update. “The completion of enrollment in our Phase ...",
"For the three months ended June 30, 2023 2022 Change % € € € Research and development expenses 7 % General and administrative expenses 1 % Total operating expenses 5 % Operating loss 5 % Finance income 651,670 11,501,804 % Loss before tax 121 % Income taxes 2,646,924 % Loss for the period 74 % Revenues We did not generate any revenues for the three months ended June 30, 2023 and June 30, 2022. Research and development expenses For the three months ended June 30, 2023 2022 Change % € € € Personnel expenses 48 % Clinical expenses 6 % Nonclinical expenses 64 % Manufacturing costs 1,682,716 % Intellectual Property costs 112 % Total research and development expenses 7 % Research and development expenses increased from €13,721,637 for...",
"Unaudited Condensed Consolidated Interim Financial Statements As of and for the",
"RISK FACTORS The following risk factors should be read in conjunction with, and amend and supplement, those included in the Annual Report on Form 20-F filed by Pharvaris N.V. on April 5, 2023 . Investing in the Company’s ordinary shares involves a high degree of risk. You should carefully consider the risks described below, and all other information contained in or incorporated by reference in the Form 20-F, before making an investment decision regarding the Company’s securities. Defined terms used, but not defined, in these “Risk Factors” have the meaning ascribed to them in the Form 20-F. Risks Related to the Development and Clinical Testing of Our Product Candidates We have experienced, and may continue to experience, setbacks in our clinical trials, including as a result ..." |
|
| 05/08/2023 |
6-K
| Quarterly results|
Docs:
|
"6-K",
"Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update • Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treatment of HAE, anticipated by YE2023 • Executing from a strong financial position with cash and cash equivalents of €135 million as of March 31, 2023 Zug, Switzerland, May 8, 2023 – Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. “The Pharvaris team has made strong progress advancing our key studies and initiatives toward meaningful year-end milestones, including the anticipated...",
"For the three months ended March 31, 2023 2022 Change % Research and development expenses 2 % General and administrative expenses 25 % Total operating expenses 9 % Operating loss 9 % Finance income 3,391,179 % Loss before tax 41 % Income taxes 57 % Loss for the period 41 % Revenues We did not generate any revenues for the three months ended March 31, 2023 and March 31, 2022. Research and development expenses For the three months ended March 31, 2023 2022 Change % Personnel expenses 67 % Clinical expenses 1,697,618 % Nonclinical expenses 237 % Manufacturing costs 1,557,438 % Intellectual Property costs — 138,603 % Total research and development expenses 2 % Research and development expenses increased from €13,514,488 for the three months ended March 31, 2022 to €13...",
"Pharvaris N.V. Unaudited Condensed Consolidated Interim Financial Statements At March 31, 2023 Contents Unaudited condensed consolidated statements of Loss and Comprehensive Loss 3 Unaudited condensed consolidated statements of financial position 4 Unaudited condensed consolidated statements of changes in equity 5 Unaudited condensed consolidated statements of cash flows 6 Notes to the unaudited condensed consolidated interim financial statements 7 2 Unaudited condensed consolidated statements of loss and other comprehensive loss Three months ended March 31, 2023 2022 Notes € € Research and development expenses 3 General and administrative expenses 4 Total operating expenses Finance income 6 3,391,179 Loss before income tax Income taxes 7 Net Loss Other comprehensive in..." |
|
| 04/05/2023 |
6-K
| Quarterly results|
Docs:
|
"6-K",
"Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update • Top-line data from CHAPTER-1, a proof-of-concept Phase 2 study of PHVS416 for the prophylactic treatment of HAE, anticipated in 2H2023 • 26-week non-clinical toxicology study intended to address the clinical holds in the U.S. initiated; submission of study results anticipated by YE2023 • Adoption of deucrictibant as the global nonproprietary name for PHA121 • Executing from a strong financial position with cash and cash equivalents of €162 million as of December 31, 2022 Zug, Switzerland, April 5, 2023 – Pharvaris , a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema attacks, today r..." |
|
| 12/08/2022 |
6-K
| Quarterly results |
| 09/12/2022 |
6-K
| Quarterly results |
| 03/29/2022 |
6-K
| Quarterly results |
| 11/10/2021 |
6-K
| Quarterly results |
| 07/30/2021 |
6-K
| Quarterly results |
| 05/26/2021 |
6-K
| Quarterly results |
|
|